Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riboflavin Dosing Regimens for Corneal Cross-Linking
NCT01143389Phase 2Completed
- Sponsor
- Price Vision Group
- Start
- May 2010
- Primary completion
- May 2017
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of riboflavin in keratoconus and corneal ectasia (2 arms), sponsored by Price Vision Group. Primary endpoint: Change in Maximum Keratometry From Baseline at 6 months. Started May 2010; status: completed.
02
Drugs
riboflavin
03
Conditions
keratoconuscorneal ectasia
Beyond the preview
Go deeper on NCT01143389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01143389.